We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+3.07%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
AUM
$1.62M
AUM Growth
-$789M
Cap. Flow
+$604M
Cap. Flow %
37,256.4%
Top 10 Hldgs %
16.56%
Holding
402
New
38
Increased
331
Reduced
2
Closed
31

Sector Composition

Rank Sector Weight
1 Industrials 20.52%
2 Technology 12.84%
3 Financials 11.72%
4 Healthcare 11.37%
5 Consumer Discretionary 11.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LCI
326
DELISTED
Lannett Company, Inc.
LCI
$1.81K 0.11%
25,171
+12,227
+94% +$1.29M
AZTA icon
327
Azenta
AZTA
$1.48B
$1.8K 0.11%
173,210
+81,007
+88% +$773K
ANGI icon
328
Angi Inc
ANGI
$196M
$1.8K 0.11%
+22,264
New +$1.92M
ASXC
329
DELISTED
Asensus Surgical, Inc.
ASXC
$1.79K 0.11%
32,358
+1,524
+5% +$65.3K
VTA
330
DELISTED
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
$1.78K 0.11%
166,004
+84,888
+105% +$866K
FLIR
331
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
$1.78K 0.11%
54,046
+18,803
+53% +$581K
DE icon
332
Deere & Co
DE
$168B
$1.75K 0.11%
22,786
+9,550
+72% +$748K
MRK icon
333
Merck
MRK
$318B
$1.73K 0.11%
34,265
+18,139
+112% +$888K
PFE icon
334
Pfizer
PFE
$153B
$1.66K 0.1%
59,178
+30,953
+110% +$884K
ICLR icon
335
Icon
ICLR
$12.7B
$1.66K 0.1%
22,108
+11,874
+116% +$832K
RACE icon
336
Ferrari
RACE
$72.5B
$1.63K 0.1%
+39,350
New +$1.59M
PNC icon
337
PNC Financial Services
PNC
$101B
$1.49K 0.09%
17,566
+8,246
+88% +$702K
FPRX
338
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.43K 0.09%
35,296
+16,412
+87% +$564K
JPC icon
339
Nuveen Preferred & Income Opportunities Fund
JPC
$2.9B
$1.43K 0.09%
153,060
+78,264
+105% +$723K
CLLS
340
Cellectis
CLLS
$285M
$1.37K 0.08%
49,870
+23,273
+88% +$561K
NVS icon
341
Novartis
NVS
$297B
$1.37K 0.08%
21,048
+10,996
+109% +$748K
XNCR icon
342
Xencor
XNCR
$1.55B
$1.35K 0.08%
100,866
+48,268
+92% +$571K
AGEN
343
Agenus
AGEN
$290M
$1.34K 0.08%
16,364
+7,637
+88% +$515K
AZN icon
344
AstraZeneca
AZN
$250B
$1.28K 0.08%
22,767
+10,863
+91% +$653K
ADXS
345
DELISTED
Advaxis Inc
ADXS
$1.25K 0.08%
9,194
+4,290
+87% +$475K
CELG
346
DELISTED
Celgene Corp
CELG
$1.17K 0.07%
11,730
+5,435
+86% +$560K
JUNO
347
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.15K 0.07%
30,320
+14,071
+87% +$490K
ADAP
348
DELISTED
Adaptimmune Therapeutics
ADAP
$1.15K 0.07%
141,086
+65,546
+87% +$536K
TCRT icon
349
Alaunos Therapeutics
TCRT
$4.86M
$1.1K 0.07%
992
+475
+92% +$486K
BLUE
350
DELISTED
bluebird bio
BLUE
$976 0.06%
1,771
+823
+87% +$505K

Similar funds

Vident Investment Advisory's Q1 2016 Portfolio in Review

As of Q1 2016, Vident Investment Advisory held 402 positions worth $1.62M, down 100% from $791M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Vident Investment Advisory deployed $604M of net new capital in Q1 2016, opening 38 new positions and adding to 331 existing holdings. Its largest new stake was Alphabet (Google) Class C: 177,120 shares worth $6.6K.

By sector, the portfolio is most concentrated in Industrials at 21% of assets, up from 9.8% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was TIME WARNER CABLE INC NEW COM STK, an estimated $684K trimmed.

  • Vident Investment Advisory's largest Q1 2016 buy was Alphabet (Google) Class C: 177,120 shares worth $6.6K.
  • Vident Investment Advisory added most to Amazon in Q1 2016, an estimated $12M increase.
  • Vident Investment Advisory's biggest Q1 2016 reduction was TIME WARNER CABLE INC NEW COM STK, cutting an estimated $684K.
  • Vident Investment Advisory fully exited State Street SPDR S&P 500 ETF Trust in Q1 2016, selling an estimated $91.8M.
  • Vident Investment Advisory's ten largest holdings make up 17% of its $1.62M portfolio in Q1 2016.
  • Vident Investment Advisory opened 38 new positions and closed 31 in Q1 2016.
  • Vident Investment Advisory's portfolio value fell 100% quarter-over-quarter to $1.62M.

Based on Vident Investment Advisory's 13F filing for Q1 2016, filed 23 May 2016.